{
    "2021-10-28": [
        [
            {
                "time": "2021-10-15",
                "original_text": "Additional VerzenioÂ® (abemaciclib) Phase 3 monarchE Trial Data Published in the Annals of Oncology",
                "features": {
                    "keywords": [
                        "Verzenio",
                        "abemaciclib",
                        "Phase 3",
                        "monarchE",
                        "Trial Data",
                        "Annals of Oncology"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-11-20",
                "original_text": "Down 76%: Is Cortexyme Stock a Bargain?",
                "features": {
                    "keywords": [
                        "Cortexyme",
                        "Stock",
                        "Bargain",
                        "Down 76%"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2022-02-10",
                "original_text": "Inventiva Plans To Start Lanifibranor Combo Study In NASH, Diabetes In 2022",
                "features": {
                    "keywords": [
                        "Inventiva",
                        "Lanifibranor",
                        "Combo Study",
                        "NASH",
                        "Diabetes",
                        "2022"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2022-03-05",
                "original_text": "Cortexyme's Alzheimer's Drug Fails -- 2 Lessons for Investors",
                "features": {
                    "keywords": [
                        "Cortexyme",
                        "Alzheimer's",
                        "Drug",
                        "Fails",
                        "Lessons",
                        "Investors"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}